US 2003/0149258 A1Published application

Multiplex PCR primer set for human HNF-1alpha gene amplification

AssigneeSamsung Electronics Co., Ltd.

InventorsYeon-Su Lee, Mi-Kyung Kim, Jung-Nam Lee

Life of this patent

Estimating the term…

Abstract

The present invention provides a primer pool for amplifying a target sequence of a human HNF-1α gene including at least one set of primers or variant primers thereof, each set of primers being identified by two consecutive SEQ ID NOS, the SEQ ID NOS starting at SEQ ID NO. 3 and terminating at SEQ ID NO. 22 according to the present invention. A target sequence such as the human HNF-1α gene may be amplified with a high specificity, a high speed, a high sensitivity and a low cost through a multiplex PCR to detect a maturity-onset of diabetes of the young (MODY) 3 associated gene.

Claims20

Dependent claims

A primer pool comprising at least one set of primers for amplifying at least one target sequence of a human HNF-1α gene, the at least one set of primers being selected from the group consisting of:

(a) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 3 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 4 or a variant oligonucleotide thereof;
(b) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 5 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 6 or a variant oligonucleotide thereof;
(c) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 7 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 8 or a variant oligonucleotide thereof;
(d) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 9 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 10 or a variant oligonucleotide thereof;
(e) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 11 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 12 or a variant oligonucleotide thereof;
(f) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 13 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 14 or a variant oligonucleotide thereof;
(g) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 15 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 16 or a variant oligonucleotide thereof;
(h) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 17 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 18 or a variant oligonucleotide thereof;
(i) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 19 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 20 or a variant oligonucleotide thereof;
and
(j) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 21 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 22 or a variant oligonucleotide thereof,
wherein said variant oligonucleotide is an oligonucleotide having 1 to 3 additional nucleotides joined or deleted from the 3′ end, the 5′ end, or both the 3′ end and the 5′ end of the corresponding oligonucleotide.

9 more elements

A method for amplifying at least one target sequence of a human HNF-1α gene comprising subjecting the at least one target sequence of a human HNF-1α gene to a PCR using at least one set of primers selected from the group consisting of:

(a) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 3 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 4 or a variant oligonucleotide thereof;
(b) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 5 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 6 or a variant oligonucleotide thereof;
(c) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 7 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 8 or a variant oligonucleotide thereof;
(d) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 9 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 10 or a variant oligonucleotide thereof;
(e) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 11 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 12 or a variant oligonucleotide thereof;
(f) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 13 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 14 or a variant oligonucleotide thereof;
(g) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 15 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 16 or a variant oligonucleotide thereof;
(h) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 17 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 18 or a variant oligonucleotide thereof;
(i) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 19 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 20 or a variant oligonucleotide thereof;
and
(j) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 21 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 22 or a variant oligonucleotide thereof,
wherein said variant oligonucleotide is an oligonucleotide having 1 to 3 additional nucleotides joined or deleted from the 3′ end, the 5′ end, or both the 3′ end and the 5′ end of the corresponding oligonucleotide.

9 more elements

A method for sequencing at least one target nucleotide sequence of a human HNF-1α gene by using at least one set of primers selected from the group consisting of:

(a) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 3 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 4 or a variant oligonucleotide thereof;
(b) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 5 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 6 or a variant oligonucleotide thereof;
(c) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 7 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 8 or a variant oligonucleotide thereof;
(d) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 9 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 10 or a variant oligonucleotide thereof;
(e) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 11 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 12 or a variant oligonucleotide thereof;
(f) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 13 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 14 or a variant oligonucleotide thereof;
(g) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 15 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 16 or a variant oligonucleotide thereof;
(h) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 17 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 18 or a variant oligonucleotide thereof;
(i) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 19 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 20 or a variant oligonucleotide thereof;
and
(j) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 21 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 22 or a variant oligonucleotide thereof,
wherein said variant oligonucleotide is an oligonucleotide having 1 to 3 additional nucleotides joined or deleted from the 3′ end, the 5′ end, or both the 3′ end and the 5′ end of the corresponding oligonucleotide.

9 more elements

A method of characterizing a test sample for diabetes comprising amplifying at least one target sequence of a human HNF-1α gene comprising at least one set of primers selected from the group consisting of:

(a) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 3 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 4 or a variant oligonucleotide thereof;
(b) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 5 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 6 or a variant oligonucleotide thereof;
(c) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 7 or a variant oliqonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 8 or a variant oligonucleotide thereof;
(d) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 9 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 10 or a variant oligonucleotide thereof;
(e) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 11 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 12 or a variant oligonucleotide thereof;
(f) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 13 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 14 or a variant oligonucleotide thereof;
(g) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 15 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 16 or a variant oligonucleotide thereof;
(h) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 17 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 18 or a variant oligonucleotide thereof;
(i) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 19 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 20 or a variant oligonucleotide thereof;
and
(j) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 21 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 22 or a variant oligonucleotide thereof,
wherein said variant oligonucleotide is an oligonucleotide having 1 to 3 additional nucleotides joined or deleted from the 3′ end, the 5′ end, or both the 3′ end and the 5′ end of the corresponding oligonucleotide.

9 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/320,095Filed 16 Dec 2002
Priority: KR 2001-8090918 Dec 2001
Published: 7 Aug 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

C12Q 1/6853
Nucleic acid amplification reactions: using modified primers or templates
C12Q 1/6827
Hybridisation assays: for detection of mutation or polymorphism
C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C12Q 2600/16
Oligonucleotides characterized by their use: primer sets for multiplex assays

Family

US 7,208,272 B2Related patent
US 2003/0149258 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A primer pool comprising at least one set of primers for amplifying at least one target sequence of a human HNF-1α gene, the at least one set of primers being selected from the group consisting of:

(a) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 3 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 4 or a variant oligonucleotide thereof;
(b) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 5 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 6 or a variant oligonucleotide thereof;
(c) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 7 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 8 or a variant oligonucleotide thereof;
(d) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 9 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 10 or a variant oligonucleotide thereof;
(e) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 11 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 12 or a variant oligonucleotide thereof;
(f) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 13 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 14 or a variant oligonucleotide thereof;
(g) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 15 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 16 or a variant oligonucleotide thereof;
(h) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 17 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 18 or a variant oligonucleotide thereof;
(i) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 19 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 20 or a variant oligonucleotide thereof;
and
(j) a set of primers comprising an oligonucleotide having a sequence given herein as SEQ ID NO. 21 or a variant oligonucleotide thereof and an oligonucleotide having a sequence given herein as SEQ ID NO. 22 or a variant oligonucleotide thereof,
wherein said variant oligonucleotide is an oligonucleotide having 1 to 3 additional nucleotides joined or deleted from the 3′ end, the 5′ end, or both the 3′ end and the 5′ end of the corresponding oligonucleotide.

9 more elements

Facts

Application

10/320,095Filed 16 Dec 2002

Priority

KR 2001-8090918 Dec 2001

Published

7 Aug 2003

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

C12Q 1/6853
Nucleic acid amplification reactions: using modified primers or templates
C12Q 1/6827
Hybridisation assays: for detection of mutation or polymorphism
C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C12Q 2600/16
Oligonucleotides characterized by their use: primer sets for multiplex assays